Vincent Med's respiratory humidifier and ventilator bag EUA in US

Hong Kong-based Vincent Medical (01612.HK) announced receipt of Emergency Use Authorization (EUA) from the US FDA for respiratory humidifier Inspired O2FLO and non-invasive ventilator ST730. Inspired O2FLO is a non-invasive high-flow oxygen therapy device outputting heated and humidified gas to patients with autonomous respiration, used to treat pneumonia, viral pneumonia (such as COVID-19), chronic obstructive pulmonary disease (COPD) and asthma. It has already been certified in Japan, Europe, and China in August 2018, November 2019 and February 2020 respectively. Since the new coronavirus outbreak at the end of 2019, Vincent Medical has delivered more than 1,700 Inspired O2FLO devices to China, the UK, Spain, Denmark, Norway, Turkey, Vietnam and South Africa.

ST730 is specially designed to provide non-invasive positive airway pressure ventilation to patients over 30kg suffering from obstructive sleep apnea (OSA) or respiratory insufficiency. It is intended for hospital and home use, but not for patients depending on mechanical ventilation. Approved in China in May 2018 and Europe in November 2018, ST730 has been used in China to treat dyspnea in COVID-19 patients since January 2020.


Related news
China-based Lee’s Pharmaceutical Holdings Ltd (950.HK) announced first patient enrollment in a key Phase III clinical study for mood disorder inhalant loxapine in China.
  • 1589341208687
  • China
  • Drug
Colombia’s National Food and Drug Surveillance Institute (INVIMA) last month published a list of medical products used to treat COVID-19 symptoms and complications whose pending regulatory processes will be given priority.
China-based biotech BeiGene (Nasdaq.BGNE; HKEX.06160) is launching a clinical trial in the United States assessing its Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) as a treatment for patients with later-stage COVID-19.
US-based pharma Gilead Sciences Inc., (Nasdaq.GILD) released results from a 53 patient cohort study assessing the experimental antiviral drug remdesivir in treating patients hospitalized due to COVID-19.
  • 1586760462607
  • China
  • Drug
US-based Ansun Biopharma Inc., revealed encouraging preliminary data from an investigator initiated study for the firm’s DAS181 as a treatment for severe COVID-19 infection.
Recent news
Colombia’s Financial Corporation for Territorial Development (FINDETER), a state-owned banking corporation, last week announced a COP 256 billion (USD 68 million) credit line for health plans and health institutions hit by the global economic downturn.
Hebei's provincial Healthcare Commission bureau released a notice setting out a broad range of medical reforms, linking together medical care, medical insurance, pharmaceuticals pricing, and in particular centralized drug procurement.
Carlos da Costa, an officer at Brazil’s Ministry of Economy (MoE), last week commented on the postponement in the allowed increase in drug prices for 2020, a measure that was announced in the end of March and is aimed at supporting patients during the COVID-19 outbreak.
China is ramping up appointment diagnosis and treatment systems and intelligent hospital infrastructure.
Argentine drug maker Elea-Phoenix has purchased two established products from Sanofi, continuing the French firm’s divestment of its over-the-counter (OTC) drugs and expanding on a previous deal between the two firms announced in March this year.
Wu Depei, CPPCC member and hematology department director at the First Affiliated Hospital of Soochow University, suggested immune thrombocytopenia (ITP) be included in medical insurance schemes.
China-based Lee’s Pharmaceutical Holdings Ltd (950.HK) released its Q1 2020 financial report, recording income down 3.5% year-on-year (YOY) to HKD 273 million (USD 35.2 million), and net profits down 15% YOY to HKD 39.9 million (USD 5.2 million). Sales for Lee’s Pharma surgery drugs hemocoagulase and low-molecular-weight heparin calcium decreased 34.8% and 33.1% respectively, as non-emergency surgeries were deprioritized by hospitals due to the COVID-19 pandemic.
Analytics Snapshot

Analytics Snapshot